Healthcare Reform – Research Stimulus Provisions


The Patient Protection and Affordable Care Act (PPACA) recently passed by Congress contains two sections that establish new economic subsidies for companies engaged in research for new methods of diagnosis and treatment of human disease, the Qualifying Therapeutic Discovery Project Credit and the Cures Acceleration Network grant program. Because companies in this field tend to have a constant and pressing need for additional funding, competition for these credits and grants is likely to be intense.

Pryor Cashman Partner Stephen M. Goodman, a member of the firm’s Life Sciences practice, has prepared a brief summary of these two programs for those persons who may wish to pursue these opportunities. His update is entitled Healthcare Reform – Research Stimulus Provisions.

LOADING PDF: If there are any problems, click here to download the file.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Pryor Cashman LLP | Attorney Advertising

Written by:


Pryor Cashman LLP on:

Popular Topics
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.

Already signed up? Log in here

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.